Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 67 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Pipeline Review, H2 2016', provides in depth analysis on Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) targeted pipeline therapeutics. 

The report provides comprehensive information on the Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30)
- The report reviews Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential ands scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) Overview 7
Therapeutics Development 8
Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Products under Development by Stage of Development 8
Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Products under Development by Therapy Area 9
Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Products under Development by Indication 10
Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Products under Development by Companies 13
Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Products under Development by Universities/Institutes 15
Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 20
Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Companies Involved in Therapeutics Development 21
Asana BioSciences LLC 21
Johnson & Johnson 22
Leon-Nanodrugs GmbH 23
Millennium Pharmaceuticals Inc 24
Tokai Pharmaceuticals Inc 25
Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Drug Profiles 26
abiraterone acetate - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
abiraterone acetate - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
abiraterone acetate - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
ASN-001 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
galeterone - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
ketoconazole - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
orteronel - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
seviteronel - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
Small Molecules to Inhibit CYP17 and CYP11B2 for Prostate Cancer - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
Small Molecules to Inhibit CYP17 Lyase - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Dormant Projects 50
Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Discontinued Products 51
Steroid 17 Alpha Hydroxylase/17,20 Lyase (17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30) - Featured News & Press Releases 52
Dec 13, 2016: Innocrin Pharmaceuticals Presents Data from the Ongoing Phase 2 Trial of Seviteronel in Estrogen Receptor-positive or Triple-negative Breast Cancer (CLARITY-01) at the San Antonio Breast Cancer Symposium 52
Oct 10, 2016: Treatment outcome data from The Prostate Cancer Registry presented for the first time at the 2016 European Society for Medical Oncology Congress 53
Oct 05, 2016: Innocrin Pharmaceuticals Appoints Edwina Baskin-Bey, MD as Chief Medical Officer and Expands the Ongoing Phase 2 Study of Seviteronel in Women with Estrogen Receptor-positive or Triple-negative Breast Cancer (TNBC) 54
Sep 19, 2016: Argentum Pharmaceuticals Succeeds in Starting Patent Cancellation Trial Against Janssens ZYTIGA 55
Jul 26, 2016: Tokai Pharmaceuticals Announces Clinical Update 55
May 18, 2016: Janssen to Present Data on Abiraterone acetate at the 2016 American Society of Clinical Oncology Annual Meeting 56
May 18, 2016: Tokai Announces Publication of Three Abstracts on Galeterone at the 2016 ASCO Annual Meeting 57
May 12, 2016: Innocrin Pharmaceuticals Begins Phase 2 Study of Seviteronel in Women with Estrogen Receptor-positive or Triple-negative Breast Cancer and Expands Two Phase 2 Studies of Seviteronel in Men with Metastatic Castrate-resistant Prostate Cancer 58
Apr 26, 2016: Tokai Announces Oral Presentation on Galeterone at the 2016 AUA Annual Meeting 59
Apr 13, 2016: Tokai Announces Presentations on Galeterone at the AACR Annual Meeting 2016 59
Mar 30, 2016: Tokai Announces Dosing of First Patient in Phase 2 Expansion Study of Galeterone in Enzalutamide-Refractory mCRPC Patients 60
Mar 21, 2016: NICE recommends abiraterone for prostate cancer 60
Mar 14, 2016: Greater Survival Benefit Shown in Men with Early and Less Aggressive Metastatic Castration-Resistant Prostate Cancer Treated with ZYTIGA Plus Prednisone 62
Jan 08, 2016: Tokai Announces Presentation of New Data Highlighting Unique Galeterone Mechanism at ASCO Genitourinary Cancers Symposium 63
Jan 07, 2016: Tokai Announces Update on ARMOR3-SV and Expanded Galeterone Clinical Development Program 64

Appendix 65
Methodology 65
Coverage 65
Secondary Research 65
Primary Research 65
Expert Panel Validation 65
Contact Us 65
Disclaimer 66

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 18
Number of Products by Stage and Route of Administration, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 20
Pipeline by Asana BioSciences LLC, H2 2016 21
Pipeline by Johnson & Johnson, H2 2016 22
Pipeline by Leon-Nanodrugs GmbH, H2 2016 23
Pipeline by Millennium Pharmaceuticals Inc, H2 2016 24
Pipeline by Tokai Pharmaceuticals Inc, H2 2016 25
Dormant Projects, H2 2016 50
Discontinued Products, H2 2016 51